Is the injection a genuine swap for surgery?

For many patients weighing this decision, the answer is a cautious yes — with one important qualification about who is suitable.

The outpatient collagen scaffold injection is a separate clinical pathway, not a scaled-down version of the surgical procedure. Both the injection and the arthroscopic surgical implant use the same acellular collagen scaffold material, which self-gels within minutes of placement to provide a biological surface for cartilage repair. What differs is the delivery setting and the clinical logic: the surgical form is placed under direct vision in an operating theatre; the injection is administered under ultrasound guidance during a clinic appointment, with no incisions or general anaesthetic involved.

For patients with focal cartilage damage that has not yet reached end-stage, bone-on-bone arthritis, published clinical evidence supports the outpatient injection as a meaningful alternative to several surgical routes — not a temporary measure or a deferral, but a regenerative treatment in its own right. For those with advanced joint destruction, neither delivery form is appropriate, and joint replacement remains the indicated path.

This article covers the outpatient injection pathway.

How the collagen scaffold reaches the joint

The scaffold arrives at the joint as a liquid, delivered through a dual-chamber syringe that mixes the murine Type I collagen solution with a neutralising agent at the moment of injection. Within three to five minutes of contact with the joint environment, the material self-gels into a stable hydrogel that adheres directly to the cartilage surface.

Placement is guided by real-time ultrasound imaging throughout the procedure, carried out at an outpatient appointment without incisions, general anaesthetic, or an operating theatre. The clinician positions the needle under direct ultrasound visualisation, confirming scaffold placement before the gel sets.

Once in position, the scaffold behaves differently from a surgical implant. Rather than filling a single well-defined defect from the base upward — which is how the arthroscopically placed form of the same material works — the injected scaffold spreads as a surface coating across the worn cartilage layer. This top-down coverage can address irregular or diffuse damage not limited to one discrete lesion, all within a single in-clinic appointment. That difference in delivery geometry matters clinically: it broadens the addressable patient population and means that outcome data from the two delivery routes — surgical and injection — should not be treated as interchangeable.

The scaffold then acts as a structural matrix that host cells may use as a biological template, with stem cells from surrounding tissue migrating in over subsequent months. In published MRI series, MOCART scores — a validated measure of cartilage repair quality — progressed from approximately 65 at four weeks to above 80 at twelve months, indicating progressive tissue maturation and defect integration in most assessed cases.

What the clinical data actually show

The most consistently reported functional measure across published knee studies is the IKDC patient-reported scale. Clinical series report improvements averaging approximately 30 points — a 30-point gain clears the established minimum clinically important difference (MCID) of 16.7 by a substantial margin, meaning the majority of patients in these studies reported a noticeable, meaningful functional benefit.

Durability data are available primarily from the surgical delivery form. A prospective post-market clinical follow-up study by Jerosch and colleagues — conducted using the arthroscopically placed scaffold rather than the outpatient injection pathway — documented an improvement of 32.4 IKDC points at three-year follow-up, with the study cohort reaching a mean functional score of 80, sustained rather than regressing from earlier assessments. That longevity profile is clinically relevant context for the injection pathway, though no equivalent long-term injection-specific dataset has yet been published.

Structural repair quality is assessed independently through MRI-based MOCART scoring, which measures defect filling and tissue integration on a 0–100 scale. Published European series report MOCART scores in the range of 81.6 to 84.3 at twelve months, indicating high-quality defect coverage and good integration with surrounding native cartilage in the majority of cases assessed.

The strongest controlled comparison in the published literature comes from a 2025 prospective study of 59 wrist fracture patients (PMC12498443). At follow-up arthroscopy, scaffold-treated cases showed significantly better cartilage quality than untreated controls — median Outerbridge grade 1.5 versus 3.0 (p=0.006). No serious complications were recorded; fibrous tissue was identified in cases where defect volume had been overfilled, pointing to technique precision as a clinically important variable.

On safety, published data across a large reported caseload record a serious complication rate of approximately zero, with reoperation rates in the 3–8% range — substantially below published figures for ACI/MACI (up to 37% reoperation) and microfracture (up to 41%).

A clear limitation applies to the evidence base as a whole: most published studies are industry-supported, and no head-to-head randomised controlled trial directly comparing the outpatient injection pathway to a surgical alternative has yet been conducted.

How it compares with common surgical routes

Patients are most often comparing this pathway against one of three surgical options: marrow stimulation (microfracture), cell-based cartilage transplantation (ACI or MACI), or knee replacement. Each carries a different risk-and-benefit profile, and the comparisons below draw on parallel published datasets rather than a single head-to-head randomised trial.

Against microfracture

Microfracture is the most commonly performed first-line cartilage surgery, but it produces fibrocartilage — a stiffer, less durable repair tissue than the hyaline-like cartilage that published evidence associates with collagen scaffold regeneration. Published series also suggest that microfracture outcomes may deteriorate progressively over time, whereas scaffold-treated cohorts in follow-up studies have not shown equivalent decline. Addressable defect size is another practical difference: microfracture is generally considered suitable for lesions up to around 2–4 cm², whereas clinical published use of the scaffold extends to approximately 6 cm².

Against ACI and MACI

Cell-based procedures such as ACI and MACI achieve broadly comparable patient-reported functional improvements — in the 30–35-point IKDC range — but require a two-stage pathway: an initial biopsy to harvest the patient's own cartilage cells, a laboratory culture phase to expand those cells, and a second procedure to implant them. The injectable scaffold bypasses all cell-processing steps as a single acellular treatment. As noted in the preceding section, reoperation figures reported in the literature favour the scaffold considerably.

Against knee replacement

The injection pathway is not a competitor to arthroplasty for end-stage, bone-on-bone disease — knee replacement remains the appropriate intervention once that clinical threshold is reached. Where the scaffold may be relevant is for patients with preserved surrounding tissue who have been advised to consider replacement but have not yet reached that end stage: published clinical descriptions position it as a joint-preservation option for this group, including active patients in their sixties and seventies. Individual suitability depends on imaging and consultant assessment.

Which patients are the right fit

Candidacy is defined by what remains of the joint rather than solely by how much has been lost. The scaffold injection is suited to focal cartilage damage in the Grade 2–3 range — where meaningful articular surface is still present but wear is progressing — and is not appropriate where bone-on-bone contact is already established. Readers cannot reliably self-grade their own cartilage; the distinction between eligible and ineligible joints is made by imaging at a clinical assessment.

Age is notably absent from the exclusion criteria in the published evidence. Some surgical cartilage procedures carry implicit or explicit age considerations when weighing long-term durability; no equivalent upper limit appears in the literature for the injectable scaffold pathway. Clinical descriptions include active patients in their sixties and seventies who have been advised that surgery or replacement may be their only remaining option — a group for whom a joint-preservation pathway may warrant investigation.

One technique-sensitive risk flagged in the 2025 wrist study (PMC12498443) is relevant to patient selection: fibrous tissue formation was identified in cases where the defect had been overfilled rather than filled to the appropriate volume. This finding underlines why clinician experience and procedural precision matter when choosing where to have the treatment.

On regulatory status: the product holds CE marking for clinical use in Europe. It is not FDA-approved, and is therefore not available through standard clinical pathways in the United States.

In the UK, access is self-funded — the treatment is not currently commissioned by the NHS, and major private medical insurers do not routinely reimburse it. Patients considering this route should request transparent cost information at assessment.

For anyone in the Grade 2–3 range who is weighing this option, an individual assessment with current imaging is the appropriate starting point.

Where the evidence currently stops

Consistency across multiple independent research groups carries evidential weight that a single sponsored trial does not. The IKDC improvements reported across four separate knee studies, the MOCART structural confirmation, and the controlled wrist data from PMC12498443 — the only published study in this evidence base with a contemporaneous untreated comparator group — point in the same direction. That convergence is meaningful, even in the absence of a randomised controlled trial directly comparing the injection pathway to a surgical alternative.

The gap that matters most for a patient deciding now is not whether the treatment produces functional improvement — published data suggest it does, to a degree that exceeds established clinical thresholds — but whether it performs better than the surgical procedures it might replace. That comparison remains indirect: it rests on parallel historical datasets from different patient populations rather than concurrent head-to-head randomisation. A prospective study comparing the injection pathway against marrow stimulation in a focal knee defect population would substantially close this gap; the controlled wrist design published in 2025 represents precisely the methodology that, applied to the knee, would carry considerably more comparative weight.

For patients evaluating this option now, the evidence supports a considered clinical discussion about individual suitability. It does not yet support a confident, population-level statement that the injection pathway outperforms cartilage surgery as a category — and a well-informed patient is better served knowing that distinction than not.